Education
About Us
Working with TipRanks
Follow Us
Codexis (CDXS)
NASDAQ:CDXS
CDXS Stock Chart & Stats
$1.20
-$0.29(-5.81%)
At close: 4:00 PM EST
$1.20
-$0.29(-5.81%)
Day’s Range― - ―
52-Week Range$0.96 - $3.87
Previous CloseN/A
Volume271.47K
Average Volume (3M)1.15M
Market Cap
$88.52M
Enterprise Value$131.82M
Total Cash (Recent Filing)$59.19M
Total Debt (Recent Filing)$68.62M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Mar 11, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding90,324,390
10 Day Avg. Volume1,704,148
30 Day Avg. Volume1,146,380
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.23
Price to Sales (P/S)5.90
P/FCF Ratio-6.52
Enterprise Value/Market Cap1.49
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit3.14
Enterprise Value/Ebitda-2.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$70.80M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And LiquiditySecured cash runway through 2027, supported by expected funds from the Merck agreement, reduces financing risk and enables continued investment in growth initiatives.
Customer Growth And PipelineAddition of ten new commercial customers and a pipeline of forty prospects indicates accelerating commercial traction and potential for diversified revenue sources.
Strategic PartnershipThe $37.8 million supply assurance agreement with Merck provides committed revenue that materially improves revenue visibility and supports commercial scale-up.
Bears Say
Commercial Transition RiskA prolonged transition to new products and services may postpone revenue acceleration and compress growth expectations.
Earnings And Financial PerformanceReported third-quarter results that fell short of expectations heighten concerns about near-term profitability and could sustain investor caution.
Workforce Reduction And Execution RiskElimination of 46 positions, roughly 24% of the workforce, may disrupt operations and increase execution risk during restructuring.
Codexis News
CDXS FAQ
What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was $0.96 and its highest was $3.87 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is $88.52M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is Mar 11, 2026 which is in 7 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on Nov 06, 2025. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.149 by -$0.071.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Overvalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.03.
How many shares outstanding does Codexis have?
Codexis has 90,324,390 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.149. Following the earnings report the stock price went down -16.953%.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in CDXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Codexis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Increased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $645.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.50%
12-Months-Change
Fundamentals
Return on Equity
-114.26%
Trailing 12-Months
Asset Growth
-16.35%
Trailing 12-Months
Company Description
Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
CDXS Company Deck
CDXS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic achievements, particularly the Merck agreement and growth in the ECO Synthesis platform. These were offset by challenges in revenue decline, net losses, and the shift away from the small molecule biocatalysis business. The sentiment remains cautiously optimistic as the company transitions with new leadership and strategic focus.View all CDXS earnings summariesCDXS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
13.67% Insiders
14.89% Mutual Funds
23.90% Other Institutional Investors
37.96% Public Companies and
Individual Investors